GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2007

Silence Therapeutics and Quark Pharmaceuticals Amend AtuRNAi Agreement

  • Silence Therapeutics and Quark Pharmaceuticals reported an expansion of their current strategic technology licensing agreement.

    In April 2005 the companies signed an option and license agreement, which provided Quark with access to Silence Therapeutics’ siRNA technology, AtuRNAi.

    The expanded agreement provides Quark with options to nonexclusive licenses to develop additional molecules against three specific targets using AtuRNAi. The terms of the amendment will entitle Silence Therapeutics to milestone payments and a royalty on product sales after exercise of the options by Quark.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?